Patient and Clinician Reported Outcomes Among Patients With Actinic Keratosis Receiving Tirbanibulin for Large fiEld Application on the Face, in U.S Clinical pRactice Settings: A Pilot Initiative (CLEAR)

Inclusion Criteria: * Diagnosed with AK on the face. * Has clinically typical, visible, and discrete 4-12 AK lesions on the face. * Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face. * Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin. * Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration. * Able to read and write in English. * Provide consent to participate in the study. * Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study. Exclusion Criteria: * Patients with any dermatological condition of the face that could interfere with clinical evaluations. * Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area. * Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months. * Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study. * Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.